atherothrombotic brain infarction
Conditions
Interventions
Colchicine 0.5 mg per day for 12 months in addition to standard treatment
standard treatment
Sponsors
Japanese Red Cross Kyoto Daini Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Within 7 days of onset. 2.atherothrombotic brain infarction. 3.capable and willing to provide written informed consent. 4.Colchicine receiving group should have a history of gout or uric acid level of more than 8.0 mg per dl after hospitalization.
Exclusion criteria
Exclusion criteria: 1.pre mRS more than 3 2.Have a potential cardiac source of embolism 3.suspect of arterial dissection. 4.unavailable to MRI. 5.Life expectancy less than 1 year. 6.Contraindicated for Colchicine. 7.Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint is the first occurrence of an event of ischemic stroke recurrence during the first 12th month after treatment. The primary safety endpoint was to evaluate any adverse events and the Colchicine related side effects during the observation period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Myocardial infarction, or stroke, infection, and total mortality during the first 12th month after treatment. | — |
Countries
Japan
Contacts
Public ContactDaiki Fukunaga
Japanese red cross Kyoto daini hospital Department of Neurology
Outcome results
None listed